Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease Clinical Trial

Official title:

Phase 2, Double-Blind, Placebo-Controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00377715
• Other study ID #: DIM02
• Status: Completed
• Phase: Phase 2
• First received: September 15, 2006
• Last updated: November 9, 2015
• Start date: September 2005

Study information

• Verified date: November 2015
• Source: Medivation, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Russia: Ministry of Health of the Russian Federation
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the safety and potential benefit of Dimebon as compared to placebo in patients with mild to moderate Alzheimer's Disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 183
• Est. primary completion date: August 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

1. Males or females greater than or equal to 50 years of age.

2. Diagnosis of Alzheimer's Disease according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV TR) and Mini Mental State Exam between 10 and 24, inclusive and Modified Hachinski Ischemia Score less than or equal to 4.

3. Brain imaging such as MRI and/or CT within one year of enrollment.

4. Subjects must have a guardian or caregiver who assists the subject at least 5 days per week (at least 3 hours/day).

5. Subjects must be able to cooperate with drug administration (including the ability to ingest oral medications) and study procedures and abide by study restrictions.

6. Subjects must have at least 6 years of prior education and should have previously (in pre-Alzheimer's condition) been capable of reading, writing and communicating effectively with others.

7. Subjects must be willing and able to give informed consent or have a mentally competent legal representative authorized to provide informed consent on their behalf.

8. Residence in an assisted care facility is allowed if subject is living independently.

Exclusion Criteria:

1. Major structural brain disease

2. Major medical illness or unstable medical condition within 6 months of screening that may interfere with the subject's ability to comply with study procedures and abide by study restrictions.

3. Residence in a nursing home or assisted care facility that provides the subject with 24-hour care and supervision.

4. Women who are pregnant, nursing, or if of child-bearing potential not using a medically accepted, highly effective method of birth control.

5. Active alcohol dependence or drug abuse.

6. Use of the following medications within 60 days prior to enrollment:cognition enhancing agents, narcotic analgesics, low potency neuroleptics, antihypertensive agents with frequent Central Nervous System (CNS) side effects, anti-Parkinsonian medications, medications with central anticholinergic activity, medications for epilepsy, lithium.

7. Participation in an investigational drug or device study within 30 days prior to study entry, or 60 days prior to study entry if the investigational drug study involved therapy for Alzheimer's Disease.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease

Intervention

Drug:
• Dimebon

• Placebo

Locations

Country	Name	City	State
Russian Federation	Mental Health Research Center of Russian Academy of Medical Sciences	Moscow

Sponsors (1)

Lead Sponsor	Collaborator
Medivation, Inc.

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Alzheimer's Disease Assessment Scale - cognitive subscale		26 weeks	No
Secondary	Clinical Global Impression of Change		26 weeks	No
Secondary	Safety Assessed By Number of Participants With Adverse Events	Adverse events will be assessed through physical examinations, electrocardiograms, and clinical laboratory data (chemistry panel, complete blood count (CBC) with differential, and urinalysis). The incidence of adverse events will be summarized by severity and relationship to study treatment.	26 weeks	Yes
Secondary	Pharmacokinetic (PK) parameter of Dimebon: Cmax	Cmax: Maximum concentration	Week 1, 2, 6, 12, 18, 24. Blood PK samples will be obtained pre-dose and 1 hour post-dose for each timepoint.	Yes